Measuring progress against cancer
Over the last 40 years, we've made significant advances in the fight against cancer. Much of this progress is a result of continuous innovation, discoveries that build on those that have come before and that have transformed the way we treat many types of cancer. To keep the momentum going, we need policies that support continuous innovation--but first, we need to better understand the progress that has occurred and what gaps need to be filled.
That's why we developed the PACE Continuous Innovation Indicators™ (CII), a first-of-its-kind tool that makes it possible to visualize progress against cancer over time and gain a better understanding of the value of cancer treatments.
The CII makes it possible for researchers, policymakers, health policy experts and patient advocates to visualize progress against cancer over time, gain a better understanding of how value in cancer treatment evolves, and consider the potential impact of policy reforms on the speed of innovation. The tool permits objective comparisons, initially against 12 tumor types: breast, colorectal, endometrial, gastric, gastrointestinal stromal tumor (GIST), renal, hepatic, non-small cell lung, pancreatic, prostate, skin (melanoma), and testicular.
At the heart of CII are thousands of pieces of evidence curated by trained analysts from authoritative, published sources such as clinical trial records and meta-analyses, observational studies and historical references. The tool generates summary graphs from which a user can access supporting evidence and additional information.
The tool is now even easier to use due to an interactive user interface and enhanced data comparison capabilities in the 12 tumor types.
This brochure provides information about the new, interactive version of the PACE Continuous Innovation Indicators (CII), the first, evidence-based, customizable online tool to review progress against cancer over time. The CII aims to inform public policy discussions and other efforts to accelerate continuous innovation against cancer. This brochure explains the key features of the online tool, including the ability to easily explore underlying data, apply custom weights to the analysis, and compare when evidence supporting treatments is published in relation to when treatments receive regulatory approval.